Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.54 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (epididymal efferent duct absorptive cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: tapentadol, amitriptyline, amitifadine +101 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 5 Parkinson's papers of 230 | 0.76 |
| pathways Reactome | 2 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 11466
Earlier readings: 2026-10-26 0.52; 2026-10-25 0.52; 2026-10-24 0.52; 2026-10-23 0.52.
Sealed predictions
- SLC6A2 in dopamine neurons, braak-0.27 (p 0.485) → -0.35 (p 0.360)receipt 0168
Swarm cases
receipt 0168: SLC6A2 in dopamine neurons, braak
- power
- full sample -0.37 (p 0.132, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.026, n 18). not the mix.
- skeptic
- leave-one-out range -0.53 to -0.29, sign flips 0; without severely affected donors -0.37 (p 0.132, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC6A2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts